300 related articles for article (PubMed ID: 17189388)
41. Rapamycin together with herceptin significantly increased anti-tumor efficacy compared to either alone in ErbB2 over expressing breast cancer cells.
Wang LH; Chan JL; Li W
Int J Cancer; 2007 Jul; 121(1):157-64. PubMed ID: 17304506
[TBL] [Abstract][Full Text] [Related]
42. Beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis.
Guo W; Pylayeva Y; Pepe A; Yoshioka T; Muller WJ; Inghirami G; Giancotti FG
Cell; 2006 Aug; 126(3):489-502. PubMed ID: 16901783
[TBL] [Abstract][Full Text] [Related]
43. Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin.
Yuste L; Montero JC; Esparís-Ogando A; Pandiella A
Cancer Res; 2005 Aug; 65(15):6801-10. PubMed ID: 16061662
[TBL] [Abstract][Full Text] [Related]
44. Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol.
Yu D; Liu B; Jing T; Sun D; Price JE; Singletary SE; Ibrahim N; Hortobagyi GN; Hung MC
Oncogene; 1998 Apr; 16(16):2087-94. PubMed ID: 9572489
[TBL] [Abstract][Full Text] [Related]
45. Suppression of receptor-mediated apoptosis by death effecter domain recruiting domain binding peptide aptamer.
Kim GS; Park YA; Choi YS; Choi YH; Choi HW; Jung YK; Jeong S
Biochem Biophys Res Commun; 2006 May; 343(4):1165-70. PubMed ID: 16581027
[TBL] [Abstract][Full Text] [Related]
46. The ErbB2/Neu/HER2 receptor is a new calmodulin-binding protein.
Li H; Sánchez-Torres J; Del Carpio A; Salas V; Villalobo A
Biochem J; 2004 Jul; 381(Pt 1):257-66. PubMed ID: 15080792
[TBL] [Abstract][Full Text] [Related]
47. A phosphoproteomic analysis of the ErbB2 receptor tyrosine kinase signaling pathways.
Mukherji M; Brill LM; Ficarro SB; Hampton GM; Schultz PG
Biochemistry; 2006 Dec; 45(51):15529-40. PubMed ID: 17176074
[TBL] [Abstract][Full Text] [Related]
48. Direct binding of Copine3 with Jab1 activates downstream ErbB2 signaling and motility in SKBr3 breast cancer cells.
Choi HY; Park N; Na JB; Ko ES; Park JY; Yoo JC
Oncol Rep; 2016 Feb; 35(2):1147-52. PubMed ID: 26719032
[TBL] [Abstract][Full Text] [Related]
49. Modulation of Nr-13 antideath activity by peptide aptamers.
Nouvion AL; Thibaut J; Lohez OD; Venet S; Colas P; Gillet G; Lalle P
Oncogene; 2007 Feb; 26(5):701-10. PubMed ID: 16909120
[TBL] [Abstract][Full Text] [Related]
50. A genome-wide RNAi screen identifies novel targets of neratinib sensitivity leading to neratinib and paclitaxel combination drug treatments.
Seyhan AA; Varadarajan U; Choe S; Liu Y; McGraw J; Woods M; Murray S; Eckert A; Liu W; Ryan TE
Mol Biosyst; 2011 Jun; 7(6):1974-89. PubMed ID: 21487605
[TBL] [Abstract][Full Text] [Related]
51. Analysis of heregulin-induced ErbB2 phosphorylation with a high-throughput Kinase receptor activation enzyme-linked immunosorbant assay.
Sadick MD; Sliwkowski MX; Nuijens A; Bald L; Chiang N; Lofgren JA; Wong WL
Anal Biochem; 1996 Mar; 235(2):207-14. PubMed ID: 8833330
[TBL] [Abstract][Full Text] [Related]
52. ErbB receptors and signaling pathways in cancer.
Hynes NE; MacDonald G
Curr Opin Cell Biol; 2009 Apr; 21(2):177-84. PubMed ID: 19208461
[TBL] [Abstract][Full Text] [Related]
53. Generation and functional characterization of intracellular antibodies interacting with the kinase domain of human EGF receptor.
Hyland S; Beerli RR; Barbas CF; Hynes NE; Wels W
Oncogene; 2003 Mar; 22(10):1557-67. PubMed ID: 12629519
[TBL] [Abstract][Full Text] [Related]
54. In vivo identification of the interaction site of ErbB2 extracellular domain with its autoinhibitor.
Hu P; Feng J; Zhou T; Wang J; Jing B; Yu M; Hu M; Zhang X; Shen B; Guo N
J Cell Physiol; 2005 Dec; 205(3):335-43. PubMed ID: 15920761
[TBL] [Abstract][Full Text] [Related]
55. An ErbB-3 antibody, MP-RM-1, inhibits tumor growth by blocking ligand-dependent and independent activation of ErbB-3/Akt signaling.
Sala G; Traini S; D'Egidio M; Vianale G; Rossi C; Piccolo E; Lattanzio R; Piantelli M; Tinari N; Natali PG; Muraro R; Iacobelli S;
Oncogene; 2012 Mar; 31(10):1275-86. PubMed ID: 21822299
[TBL] [Abstract][Full Text] [Related]
56. Decorin prevents metastatic spreading of breast cancer.
Reed CC; Waterhouse A; Kirby S; Kay P; Owens RT; McQuillan DJ; Iozzo RV
Oncogene; 2005 Feb; 24(6):1104-10. PubMed ID: 15690056
[TBL] [Abstract][Full Text] [Related]
57. Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2.
Longva KE; Pedersen NM; Haslekås C; Stang E; Madshus IH
Int J Cancer; 2005 Sep; 116(3):359-67. PubMed ID: 15800944
[TBL] [Abstract][Full Text] [Related]
58. Identification of a small peptide that inhibits the phosphorylation of ErbB2 and proliferation of ErbB2 overexpressing breast cancer cells.
Pero SC; Shukla GS; Armstrong AL; Peterson D; Fuller SP; Godin K; Kingsley-Richards SL; Weaver DL; Bond J; Krag DN
Int J Cancer; 2004 Oct; 111(6):951-60. PubMed ID: 15300809
[TBL] [Abstract][Full Text] [Related]
59. Ventricular ErbB2/ErbB4 activation and downstream signaling in pacing-induced heart failure.
Doggen K; Ray L; Mathieu M; Mc Entee K; Lemmens K; De Keulenaer GW
J Mol Cell Cardiol; 2009 Jan; 46(1):33-8. PubMed ID: 19010331
[TBL] [Abstract][Full Text] [Related]
60. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies.
Yu D; Hung MC
Oncogene; 2000 Dec; 19(53):6115-21. PubMed ID: 11156524
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
